Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#71 / 200 Total
WORX - SCWorx Corp - Stock Price Chart
TickerWORX [NASD]
CompanySCWorx Corp
CountryUSA
IndustryHealth Information Services
Market Cap1.85MEPS (ttm)-1.69
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y62.68%
P/S0.47EPS next 5Y-
P/B0.30EPS Q/Q-53.45%
Dividend-Sales Q/Q-8.19%
Insider Own6.28%Inst Own2.71%
Insider Trans0.00%Inst Trans-35.91%
Short Float1.15%Earnings-
Analyst Recom-Target Price-
Avg Volume354.24K52W Range1.13 - 6.82
SCWorx Corp. engages in the development of software for healthcare providers. It provides data normalization, application interoperability, and big data analytics. The company was founded by Marc S. Schessel in 2012 and is headquartered in New York, NY.
SPCE - Virgin Galactic Holdings Inc - Stock Price Chart
TickerSPCE [NYSE, RUT]
CompanyVirgin Galactic Holdings Inc
CountryUSA
IndustryAerospace & Defense
Market Cap153.25MEPS (ttm)-25.03
P/E-EPS this Y37.70%
Forward P/E-EPS next Y25.07%
PEG-EPS past 5Y-15.86%
P/S18.27EPS next 5Y19.40%
P/B0.36EPS Q/Q55.49%
Dividend-Sales Q/Q406.38%
Insider Own8.45%Inst Own40.63%
Insider Trans0.00%Inst Trans18.44%
Short Float31.60%EarningsAug 07/a
Analyst Recom3.10Target Price39.83
Avg Volume2.18M52W Range6.22 - 86.40
Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ahrens Douglas TChief Financial OfficerJul 17 '24Option Exercise0.001,377028,923Jul 19 04:08 PM
Colglazier Michael ACEO and PresidentJul 17 '24Option Exercise0.002,273043,141Jul 19 04:08 PM
Chitale AparnaEVP, Chief People OfficerJul 17 '24Option Exercise0.00525010,688Jul 19 04:07 PM
Chitale AparnaEVP, Chief People OfficerApr 09 '24Option Exercise0.0041,9580230,108Apr 11 08:45 PM
Colglazier Michael ACEO and PresidentApr 09 '24Option Exercise0.00181,8180951,896Apr 11 08:44 PM
LFWD - Rewalk Robotics Ltd. - Stock Price Chart
TickerLFWD [NASD]
CompanyRewalk Robotics Ltd.
CountryIsrael
IndustryMedical Devices
Market Cap36.54MEPS (ttm)-2.82
P/E-EPS this Y25.87%
Forward P/E-EPS next Y60.16%
PEG-EPS past 5Y52.11%
P/S2.04EPS next 5Y-
P/B0.89EPS Q/Q-43.76%
Dividend-Sales Q/Q329.51%
Insider Own21.47%Inst Own3.19%
Insider Trans0.16%Inst Trans-31.39%
Short Float2.49%EarningsMay 15/b
Analyst Recom1.00Target Price6.90
Avg Volume22.80K52W Range3.41 - 9.10
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Yokneam Ilit, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch JeannineVP of Market Access & StrategyJul 01 '24Sale3.831,8347,01851,066Jul 02 05:02 PM
Jasinski Lawrence JChief Executive OfficerJun 18 '24Sale4.223,46614,617105,974Jun 21 08:47 AM
Turk Joseph E JrDirectorMay 23 '24Buy5.017,91639,65912,516May 24 08:17 PM
Lawless Michael AChief Financial OfficerMay 23 '24Buy4.972,0009,9404,150May 28 04:42 PM
Turk Joseph E JrDirectorMay 22 '24Buy5.01844214,600May 24 08:17 PM
CDTX - Cidara Therapeutics Inc - Stock Price Chart
TickerCDTX [NASD]
CompanyCidara Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap93.21MEPS (ttm)-8.07
P/E-EPS this Y-136.67%
Forward P/E26.13EPS next Y104.12%
PEG-EPS past 5Y37.54%
P/S2.01EPS next 5Y-
P/B-EPS Q/Q-458.81%
Dividend-Sales Q/Q-67.44%
Insider Own4.04%Inst Own27.53%
Insider Trans-20.45%Inst Trans15.73%
Short Float1.69%EarningsMay 15/a
Analyst Recom1.00Target Price25.00
Avg Volume49.29K52W Range10.00 - 24.40
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stein JeffreyPresident & CEOJun 07 '24Buy13.218,000105,68024,580Jun 11 06:26 PM
Tari LeslieCHIEF SCIENTIFIC OFFICERMar 11 '24Sale0.6721,02914,085258,681Mar 12 09:48 PM
Sandison TaylorChief Medical OfficerMar 11 '24Sale0.6720,66213,839347,095Mar 12 09:47 PM
Ward ShaneCOO & CLOMar 11 '24Sale0.6720,47313,713198,770Mar 12 09:46 PM
Shah PreetamCFO & CBOMar 11 '24Sale0.6718,93112,680227,210Mar 12 09:45 PM
AQST - Aquestive Therapeutics Inc - Stock Price Chart
TickerAQST [NASD, RUT]
CompanyAquestive Therapeutics Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap347.77MEPS (ttm)-0.43
P/E-EPS this Y-283.65%
Forward P/E-EPS next Y9.77%
PEG-EPS past 5Y46.61%
P/S6.75EPS next 5Y-
P/B-EPS Q/Q-259.47%
Dividend-Sales Q/Q8.25%
Insider Own12.40%Inst Own39.49%
Insider Trans-0.66%Inst Trans-2.95%
Short Float13.01%EarningsAug 06/a
Analyst Recom1.12Target Price8.56
Avg Volume1.69M52W Range1.25 - 6.23
Jul-25-24 08:00AM Aquestive Therapeutics Reports Positive Topline Data for Anaphylm (epinephrine) Sublingual Film from Self-Administration Study (GlobeNewswire)
Jul-23-24 08:00AM Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET (GlobeNewswire) +9.90%
Jun-27-24 08:00AM Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire) +7.02%
Jun-25-24 01:00PM Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows (Benzinga)
08:00AM Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jun-18-24 08:00AM Aquestive Therapeutics to Join the Russell 3000 and Russell 2000 Indexes Effective June 28, 2024 (GlobeNewswire)
Jun-03-24 08:00AM Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities (GlobeNewswire)
May-28-24 08:00AM Aquestive Therapeutics to Present Anaphylm (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference (GlobeNewswire)
May-10-24 07:11AM Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target (MT Newswires) -6.08%
May-09-24 04:51PM Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.65%
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schobel Alexander MarkChief Innovation/Tech OfficerMar 15 '24Sale6.0050,000300,000984,476Mar 19 02:30 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMar 08 '24Sale5.1925,000129,6851,040,371Mar 12 01:45 PM
RILY - B. Riley Financial Inc - Stock Price Chart
TickerRILY [NASD, RUT]
CompanyB. Riley Financial Inc
CountryUSA
IndustryFinancial Conglomerates
Market Cap561.16MEPS (ttm)-5.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.39EPS next 5Y-
P/B2.44EPS Q/Q-432.61%
Dividend16.20%Sales Q/Q-7.75%
Insider Own48.67%Inst Own37.45%
Insider Trans0.00%Inst Trans-4.22%
Short Float73.72%EarningsMay 15/a
Analyst Recom-Target Price-
Avg Volume1.04M52W Range14.46 - 60.72
B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
B. Riley Financial, Inc.10% OwnerFeb 08 '24Sale11.00852,4559,377,0050Feb 09 09:00 PM
B. Riley Financial, Inc.10% OwnerFeb 07 '24Sale11.002,757,30830,330,3880Feb 09 09:00 PM
B. Riley Financial, Inc.10% OwnerJan 23 '24Sale7.829,35373,146184,862Jan 23 09:00 PM
B. Riley Financial, Inc.10% OwnerJan 22 '24Sale7.7013,521104,066194,215Jan 23 09:00 PM
B. Riley Financial, Inc.10% OwnerJan 19 '24Sale7.5738,317290,037207,736Jan 23 09:00 PM
RR - Richtech Robotics Inc. - Stock Price Chart
TickerRR [NASD]
CompanyRichtech Robotics Inc.
CountryUSA
IndustrySpecialty Industrial Machinery
Market Cap82.80MEPS (ttm)-0.04
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S9.22EPS next 5Y-
P/B8.15EPS Q/Q-54.13%
Dividend-Sales Q/Q5.14%
Insider Own77.75%Inst Own0.08%
Insider Trans0.00%Inst Trans-
Short Float2.34%Earnings-
Analyst Recom-Target Price-
Avg Volume2.26M52W Range1.05 - 12.29
Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.
KYTX - Kyverna Therapeutics Inc. - Stock Price Chart
TickerKYTX [NASD, RUT]
CompanyKyverna Therapeutics Inc.
CountryUSA
IndustryBiotechnology
Market Cap424.30MEPS (ttm)-
P/E-EPS this Y96.30%
Forward P/E-EPS next Y-15.06%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.18EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own54.86%Inst Own38.56%
Insider Trans9.55%Inst Trans-
Short Float14.55%EarningsMay 14/a
Analyst Recom1.40Target Price42.75
Avg Volume630.83K52W Range6.75 - 35.06
Jul-16-24 11:33AM Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
WF - Woori Financial Group Inc ADR - Stock Price Chart
TickerWF [NYSE]
CompanyWoori Financial Group Inc ADR
CountrySouth Korea
IndustryBanks - Regional
Market Cap8.89BEPS (ttm)7.02
P/E5.14EPS this Y15.09%
Forward P/E4.00EPS next Y5.45%
PEG0.52EPS past 5Y-0.54%
P/S0.40EPS next 5Y9.90%
P/B0.42EPS Q/Q-
Dividend6.99%Sales Q/Q74.93%
Insider Own0.00%Inst Own2.19%
Insider Trans-Inst Trans-15.84%
Short Float0.09%EarningsJul 25/b
Analyst Recom1.83Target Price38.75
Avg Volume56.96K52W Range24.94 - 36.17
Woori Financial Group, Inc. engages in providing banking and other financial services. The company was founded on April 2, 2001 and is headquartered in Seoul, South Korea.
CBAT - CBAK Energy Technology Inc - Stock Price Chart
TickerCBAT [NASD]
CompanyCBAK Energy Technology Inc
CountryChina
IndustryElectrical Equipment & Parts
Market Cap125.02MEPS (ttm)0.10
P/E14.34EPS this Y1166.67%
Forward P/E3.76EPS next Y15.62%
PEG0.48EPS past 5Y17.82%
P/S0.57EPS next 5Y30.00%
P/B1.03EPS Q/Q803.87%
Dividend-Sales Q/Q38.74%
Insider Own20.32%Inst Own2.14%
Insider Trans0.00%Inst Trans-20.28%
Short Float1.50%EarningsMay 10/b
Analyst Recom-Target Price2.50
Avg Volume275.57K52W Range0.76 - 2.08
CBAK Energy Technology, Inc. engages in the manufacture, commercialization, and distribution of lithium-ion rechargeable batteries. Its products are used for electronic vehicles, light electric vehicles, electric tools, energy storage, uninterruptible power supply, and high-power applications. It operates through the CBAK and Hitrans segments. The CBAK segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium-ion rechargeable batteries for use in a wide array of applications. The Hitrans segment covers the development and manufacturing of NCM precursor and cathode materials. The company was founded on October 4, 1999 and is headquartered in Dalian, China.
134567891011121320